bunitrolol

was heading 1975-94 (see under PROPANOLAMINES 1975-90); KO 1366 was see BUNITROLOL 1975-94; use PROPANOLAMINES to search BUNITROLOL 1975-94; a beta-adrenergic receptor antagonist with weak antiarrhythmic activity and minor ability to decrease the heart rate

Also Known As:

Networked: 21 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Ischemia 05/01/1987 - "In contrast, ischemia at rest was apparently improved by bunitrolol because LV wall stress decreased due to the reduction in LV volume which was suggested by the decline in LV systolic pressure and LVEDP while CI remained constant. " 04/01/1993 - "After 30 min of ischemia, a beneficial effect of bunitrolol on the ischemic myocardium was not observed. " 04/01/1993 - "Pretreatment with bunitrolol at 0.3 but not 1.0 mg/kg attenuated the myocardial metabolic changes caused by 3 min of ischemia. " 04/01/1993 - "Ischemia was induced by ligating the left anterior descending coronary artery for 3 or 30 min. Bunitrolol (0.3 or 1.0 mg/kg of body weight) was injected intravenously 5 min before the onset of ischemia. " 04/01/1993 - "These results suggest that bunitrolol may lessen the ischemic influence on the myocardium in the early stage of ischemia and that intrinsic sympathomimetic action may not have a beneficial effect on the ischemic myocardium."
2.	Tachycardia (Tachyarrhythmias) 07/01/1985 - "Bunitrolol produced a tachycardia for the first 2 hr and a significant reduction in resting MAP at 3 and 4 hr after the oral dose (5 mg/kg) when plasma bunitrolol concentration was less than 10 ng/ml, indicating the difference between cardiac and vascular beta adrenoceptors in sensitivity to intrinsic sympathomimetic action or direct vasodilator action. "
3.	Body Weight (Weight, Body) 09/01/1988 - "The blood pressure of the bunitrolol-treated group did not differ from that of the untreated group, but ratio of ventricular weight to body weight was significantly lower in the treated group. " 01/01/1977 - "Measurements were made at rest, during atrial pacing at 100 beats/min, and during hand grip exercise, before and afterintravenous administration of KO.1366 at a dosage of 0.05 mg/kg body weight. " 04/01/1993 - "Ischemia was induced by ligating the left anterior descending coronary artery for 3 or 30 min. Bunitrolol (0.3 or 1.0 mg/kg of body weight) was injected intravenously 5 min before the onset of ischemia. " 01/10/1975 - "By means of a standardized, single-level ergometric load of 1.5 watt/kg body weight, the effects of a new beta-adrenergic receptor blocking agent bunitrolol (o-(2-hydroxy-3-tertiary butylamino)-propoxy)-benzonitrile) was compared with the well-known cardiovascular properties of practolol during an intraindividual therapeutic crossover trial after intravenous administration. "
4.	Stable Angina 01/01/1981 - "In 20 patients with stable angina pectoris, o-[3-(tert.-butylamino)-2-hydroxypropoxy]-benzonitrile (bunitrolol) was compared with placebo in a double blind cross-over trial, with monthly treatment periods. "
5.	Tremor (Tremors) 01/01/1982 - "In the previous study bunitrolol had no effect on tremor and blood pressure and a less marked effect on heart rate. "

Related Drugs and Biologics

1.	Sympathomimetics (Sympathomimetic Amines)
2.	Adrenergic Receptors (Adrenergic Receptor)
3.	Vasodilator Agents (Vasodilators)
4.	Practolol
5.	benzonitrile
6.	beta Adrenergic Receptors
7.	Oxprenolol (Trasicor)
8.	Metoprolol (Toprol-XL)
9.	Histamine (Histamine Dihydrochloride)
10.	Fenoterol

Related Therapies and Procedures

1.	Intravenous Administration
2.	Therapeutics
3.	Oral Administration